Related Experiment Video
Updated: Jul 4, 2025
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis
Christopher Gs Gilmartin1,2, Natasha Hoyle3, Afagh Garjani1,2
1Mental Health and Clinical Neurosciences Academic Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Background:
Siponimod-related lymphopenia in real-world clinical practice has implications for dose adjustment and infection risk.
Objective:
To characterise siponimod-related lymphopenia in people with secondary progressive multiple sclerosis (pwSPMS).
Methods:
This is a retrospective cohort of 188 pwSPMS. The development of grade 4 lymphopenia was interrogated with Kaplan-Meier survival analysis and binary logistic regression.
Results:
Lymphopenia develops soon after commencing siponimod. In total, 15 (8.5%) of 176 experienced grade 4 lymphopenia at 1 month after initiation. There were no clinically significant associations between patient characteristics and development of grade 4 lymphopenia.
Conclusion:
Grade 4 lymphopenia can occur soon after siponimod initiation and cannot be predicted.
